ArticleProteomics. Clinical applications2008
Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases.
Article in Proteomics. Clinical applications, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.Oral oncology · 2012Trial
- Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: implications for cancer risk reduction.Gynecologic oncology · 2012Trial
- Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.Oral oncology · 2011Trial
- Comparison of 46 Cytokines in Peripheral Blood Between Patients with Papillary Thyroid Cancer and Healthy Individuals with AI-Driven Analysis to Distinguish Between the Two Groups.Diagnostics (Basel, Switzerland) · 2025Article
- Evaluation of the hematological parameters, inflammatory biomarkers, and thyroid hormones in hypothyroidism patients.BMC research notes · 2024Article
- Differential gene expression profile of multinodular goiter.PloS one · 2022Article
- Microglial Heterogeneity and Its Potential Role in Driving Phenotypic Diversity of Alzheimer's Disease.International journal of molecular sciences · 2021Article
- Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines.Annals of surgical treatment and research · 2021Article
- Prognosis of Macrophage Density in the Absence of Neutrophils in Differentiated Thyroid Cancer.The Journal of surgical research · 2020Article
- Interleukins in Thyroid Cancer: From Basic Researches to Applications in Clinical Practice.Frontiers in immunology · 2020Review
- Evaluation of multiplexed biomarkers in assessment of CSF infiltration in pediatric acute lymphoblastic leukemia.International journal of hematologic oncology · 2019Article
- Effect of IL-6 on proliferation of human thyroid anaplastic cancer stem cells.International journal of clinical and experimental pathology · 2019Article
- Significance of TNF-α and the Adhesion Molecules: L-Selectin and VCAM-1 in Papillary Thyroid Carcinoma.Journal of thyroid research · 2016Article
- Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays.Mediators of inflammation · 2016Review
- Ginsenoside Rd Improves Learning and Memory Ability in APP Transgenic Mice.Journal of molecular neuroscience : MN · 2015Article
- Interleukins as markers of inflammation in malignant and benign thyroid disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2014Article
- Ginsennoside rd attenuates cognitive dysfunction in a rat model of Alzheimer's disease.Neurochemical research · 2012Article
- Data Analysis Strategies for Protein Microarrays.Microarrays (Basel, Switzerland) · 2012Review
- Article
- Clinical utility of serum interleukin-8 and interferon-alpha in thyroid diseases.Journal of thyroid research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Thyroid cancer incidence is increasing, and its diagnosis can be challenging. Fine needle biopsy, the principal clinical tool to make a tissue diagnosis, leads to inconclusive diagnoses in up to 30% of the cases, leading to surgery. Advances in proteomics are improving abilities to diagnose malignant conditions using small samples of tissue or body fluids. We hypothesized that analysis of serum growth factors would uncover diagnostically informative differences between benign and malignant thyroid conditions. Using xMAP profiling, we evaluated concentrations of 19 cytokines, chemokines, and growth factors. We used sera from 23 patients with cancer (Malignant group), 24 patients with benign nodular thyroid disease (Benign group), and 23 healthy subjects (Normal group). In univariate analysis, five factors (epithelial growth factor, hepatocyte growth factor, Interleukins-5 and -8, and regulated upon activation, normally T-expressed and presumably secreted (RANTES) distinguished subjects with thyroid disease from the Normal group. In multivariate analysis, the set {Interleukin-8, hepatocyte growth factor, monocyte-induced γ interferon, interleukin-12 p40} achieved noteworthy discrimination between Benign and Malignant groups (area under the receiver operating characteristics curve was 0.81 (95% confidence interval: 0.65-0.90)). Multiplex panels of serum biomarkers may be promising tools to diagnose cancer in patients presenting with evidence of nodular thyroid disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.